Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer
D Antoniou, G Pavlakou, GP Stathopoulos, I Karydis… - Lung Cancer, 2006 - Elsevier
… is involved in advanced lung cancer, the … disease progression. We found that D-dimer
levels dropped in responders (73.7%) while they increased in patients with disease progression (…
levels dropped in responders (73.7%) while they increased in patients with disease progression (…
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling
… C, Kaplan–Meier analysis for freedom from progression (left) and disease-… progression
from the end of treatment for all patients who experienced posttreatment disease progression by …
from the end of treatment for all patients who experienced posttreatment disease progression by …
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
ZF Lim, PC Ma - Journal of hematology & oncology, 2019 - Springer
… However, initial disease control is then followed by a relatively short progression-free …
previously shown to play a critical role in lung cancer progression [54] and co-overexpression of …
previously shown to play a critical role in lung cancer progression [54] and co-overexpression of …
Patients with IPF and lung cancer: diagnosis and management
A Tzouvelekis, P Spagnolo, F Bonella… - The Lancet …, 2018 - thelancet.com
… treated non-small-cell lung cancer, surgery-related mortality was higher (… lung cancer. Close
surveillance with yearly HRCT should be mandatory not only to monitor disease progression …
surveillance with yearly HRCT should be mandatory not only to monitor disease progression …
[HTML][HTML] Challenges in lung cancer therapy during the COVID-19 pandemic
… disease.8, 9 These radiological manifestations can overlap with CT findings that are often
found in patients with lung cancer upon disease progression … during lung cancer progression …
found in patients with lung cancer upon disease progression … during lung cancer progression …
[HTML][HTML] … overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
T Mok, DR Camidge, SM Gadgeel, R Rosell… - Annals of oncology, 2020 - Elsevier
… This was attributed to a crossover rate of more than 80% to the crizotinib arm at the point
of disease progression (PD). Median OS was NR (95% CI 45.8–NR) with crizotinib and was …
of disease progression (PD). Median OS was NR (95% CI 45.8–NR) with crizotinib and was …
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib …
… Gastrointestinal stromal tumors have a unique biology with rapid disease progression … lung
cancer when gefitinib or erlotinib are stopped because of radiographic disease progression …
cancer when gefitinib or erlotinib are stopped because of radiographic disease progression …
Breathomics in lung disease
MP Van Der Schee, T Paff, P Brinkman… - Chest, 2015 - Elsevier
… lung cancer have sufficient accuracy to establish lung cancer in … specificity of identified volatiles
for lung cancer. This may be … in pulmonary disease has hampered the progress in sensor …
for lung cancer. This may be … in pulmonary disease has hampered the progress in sensor …
[HTML][HTML] Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions
YK Chae, MS Oh - Journal of thoracic oncology, 2019 - Elsevier
… risk of disease recurrence and thus guide treatment decisions for resectable lung cancer. …
validate such approaches and expand the utility of these rapidly progressing technologies. …
validate such approaches and expand the utility of these rapidly progressing technologies. …
Evaluation of response criteria in advanced lung cancer
RT Eagan, TR Fleming, V Schoonover - Cancer, 1979 - Wiley Online Library
… cell lung cancer. These were the first five trials in patients with advanced nonsmall cell lung
cancer since we began using the evaluable disease … Time to disease progression calculated …
cancer since we began using the evaluable disease … Time to disease progression calculated …